<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866229</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-51-15</org_study_id>
    <nct_id>NCT00866229</nct_id>
  </id_info>
  <brief_title>Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level</brief_title>
  <official_title>Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early statin therapy in SLE patients that have high cholesterol level and other
      atherosclerosis risk should reduce atherosclerosis and coronary artery events in later course
      of disease. By the way, statin is used in restricted groups of rheumatologists due to
      awareness of side effects; myositis and hepatitis, that are frequently found in SLE patients
      more so than other groups of atherosclerosis patients and reporting data of autoimmune
      diseases that occur after statin use.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction of LDL Cholesterol level</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that have transminitis, myositis or active SLE</measure>
    <time_frame>6,12, 18 and 24 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>High LDL Cholesterol Level</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10 mg per day for 12 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>20 mg per day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SLE patients that on prednisolone more than 30 mg/day

          -  Normal liver faction: AST and ALT &lt; 80 mg/dl

          -  Normal muscle enzyme : CPK &lt; 100 U/L

          -  LDL cholesterol level &gt; 100 mg/dl

        Exclusion Criteria:

          -  Patients that was treated with pulse methylprednisolone or corticosteroid equivalent
             to prednisolone &gt; 1mg/kg/day at screening.

          -  Statin allergy

          -  On statin treatment before screening

          -  On cyclosporine, antifugal (azole group), antibiotics (macrolide group), rifampicin,
             warfarin, phenytoin

          -  Pregnancy

          -  Abnormal liver function: AST or ALT &gt; 80 mg/dl

          -  Abnormal muscle enzyme : CPK &gt; 300 U/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parawee Suwannalai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parawee Suwannalai, M.D.</last_name>
    <phone>+31614364578</phone>
    <email>tepwa@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Piyaporn Sirijanchun, M.D.</last_name>
    <phone>+66816810700</phone>
    <email>tepsrc@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10240</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pintip Ngamjanyaporn, M.D.</last_name>
      <phone>+6622011477</phone>
      <email>pintiptip@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Piyaporn Sirijanchun, M.D.</last_name>
      <phone>+6622011477</phone>
      <email>tepsrc@mahidol.ac.th</email>
    </contact_backup>
    <investigator>
      <last_name>Parawee Suwannalai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Parawee Suwannalai , M.D.</name_title>
    <organization>Ramathibodi Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

